Cyclosporine levels at 2 hours after dose and body mass index in relation to graft function in renal transplant patients treated with azathioprine or mycophenolate mofetil

2004 ◽  
Vol 36 (6) ◽  
pp. 1753-1756
Author(s):  
I. Konstadinidou ◽  
N. Giapraka ◽  
S. Lionaki ◽  
D. Kyriaki-Manolaraki ◽  
A. Kostakis ◽  
...  
2014 ◽  
Vol 186 (2) ◽  
pp. 686
Author(s):  
E. Myers ◽  
D. Taber ◽  
C. Bratton ◽  
J. McGillicuddy ◽  
K. Chavin ◽  
...  

2001 ◽  
Vol 33 (7-8) ◽  
pp. 3110-3111 ◽  
Author(s):  
L Hortal ◽  
A Fernández ◽  
A Losada ◽  
M Lorenzo ◽  
E Baamonde ◽  
...  

2018 ◽  
Vol 46 (11) ◽  
pp. 4617-4623 ◽  
Author(s):  
Keiko Hosohata ◽  
Etsuko Matsuoka ◽  
Ayaka Inada ◽  
Saki Oyama ◽  
Iku Niinomi ◽  
...  

Objective Immunosuppressive regimens after renal transplantation usually include a combination of calcineurin inhibitors, corticosteroids, and a proliferation inhibitor, either azathioprine or mycophenolate mofetil (MMF), to prevent rejection and maintain graft function. MMF has a stronger immunosuppressive effect than does azathioprine. This study aimed to examine MMF-associated adverse events in renal transplant patients. Methods Retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report database. Results A total of 11,594 adverse drug events were reported in renal transplant patients; 10,272 (88.6%) involved adults and 1322 (11.4%) involved children. In adult patients, the most frequent adverse events induced by MMF were cytomegalovirus infection (272 reports), urinary tract infection (69 reports), and polyomavirus-associated nephropathy (61 reports). Among adverse events, the highest reporting odds ratio (ROR) was found for cytomegalovirus infection (ROR, 1.58; 95% confidence interval, 1.36–1.83). In pediatric patients, the rank order for MMF-associated adverse events was cytomegalovirus infection (27 reports), bronchitis (23 reports), and cytomegalovirus viremia (19 reports), but these adverse events were not detected as a signal. Conclusion Our results show the safety profile of MMF in pediatric renal transplant patients. These findings can be used to update information used for prescriptions for pediatric patients.


2007 ◽  
Vol 11 (8) ◽  
pp. 860-867 ◽  
Author(s):  
Douglas M. Silverstein ◽  
Pamela LeBlanc ◽  
James M. Hempe ◽  
Thiagarajan Ramcharan ◽  
J. Philip Boudreaux

2001 ◽  
Vol 15 (2) ◽  
pp. 123-130 ◽  
Author(s):  
John M Kovarik ◽  
Mark D Pescovitz ◽  
Hans W Sollinger ◽  
Bruce Kaplan ◽  
Christophe Legendre ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document